Tecentriq Hybreza Injection
Product Images NDC 50242-933

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tecentriq Hybreza (NDC 50242-933). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Tecentriq 01)

A Kaplan-Meier curve chart showing the probability of disease-free survival over time in months. The chart compares two groups: intravenous atezolizumab and best supportive care, with survival probabilities plotted from 0 to 1 and patient risk numbers listed below the x-axis for each group at different time points up to 54 months.*

FDA Label Image

Figure 2 (Tecentriq 02)

A Kaplan-Meier survival curve comparing probability of survival over time in months between two groups: intravenous atezolizumab and chemotherapy. The graph plots survival probability on the vertical axis from 0 to 1 and time on the horizontal axis up to about 38 months, showing higher survival probability for the intravenous atezolizumab group compared to chemotherapy. Below the graph, a table lists the number of patients at risk at various time points for each treatment group.*

FDA Label Image

Figure 3 (Tecentriq 03)

A Kaplan-Meier survival curve comparing two treatment regimens over time in months with probability of survival on the y-axis. One line represents intravenous atezolizumab plus bevacizumab, paclitaxel, and carboplatin, and the other represents bevacizumab plus paclitaxel and carboplatin alone. Below the graph is a table showing the number of patients at risk for each group at various time points.*

FDA Label Image

Figure 4 (Tecentriq 04)

A Kaplan-Meier survival curve graph showing probability of survival over time in months. It compares two groups: one receiving intravenous atezolizumab plus paclitaxel protein-bound and carboplatin, and the other receiving paclitaxel protein-bound plus carboplatin. The graph includes numbers at risk for each group at various time points up to 34 months.*

FDA Label Image

Figure 5 (Tecentriq 05)

A survival probability Kaplan-Meier curve comparing intravenous atezolizumab and docetaxel over time in months. The y-axis shows probability of survival from 0 to 1.0, and the x-axis shows time up to 27 months. The graph includes a patient risk table below the x-axis indicating the number of patients at risk at various time points for both treatments.*

FDA Label Image

Figure 6 (Tecentriq 06)

A Kaplan-Meier survival curve chart illustrating overall survival percentage over time in months for two patient groups: one receiving intravenous atezolizumab plus carboplatin and etoposide, and the other receiving placebo plus carboplatin and etoposide. The chart also includes a table showing the number of patients at risk at various time points for both groups.*

FDA Label Image

Figure 7 (Tecentriq 07)

A Kaplan-Meier survival curve chart showing the probability of overall survival over time (months) comparing two treatment groups: intravenous atezolizumab plus bevacizumab and sorafenib. The chart includes patient risk numbers at various time points for each treatment group.*

FDA Label Image

Figure 8 (Tecentriq 08)

A Kaplan-Meier survival curve chart showing the probability of progression-free survival over time (months). It compares two groups: one receiving intravenous atezolizumab plus cobimetinib and vemurafenib, and the other receiving only cobimetinib plus vemurafenib. The chart includes numbers of patients remaining at risk at various time points for each group.*

FDA Label Image

Principal Display Panel (15 mL Vial Box)

Label for Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) injection, subcutaneous. The label displays strengths of 1,875 mg and 30,000 units per 15 mL (125 mg and 2,000 units per mL), indicating a single-dose vial. It includes instruction for subcutaneous use only and pharmacist dispensing guidance. The labeler is Genentech, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.